Pyxis Oncology (PYXS) Payables (2020 - 2026)

Pyxis Oncology (PYXS) has reported Payables for 7 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 65.27% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was $3.3 million, a 65.27% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, up 124.02% from the prior year.
• Payables was $3.3 million for Q2 2026 at Pyxis Oncology, down from $10.9 million in the prior quarter.
• Over five years, Payables peaked at $10.9 million in Q4 2025 and troughed at $1.3 million in Q2 2023.
• A 5-year average of $5.2 million and a median of $4.9 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables tumbled 83.31% in 2023 and jumped 319.16% in 2024, its largest moves.
• Over 5 years, Payables stood at $7.1 million in 2022, then tumbled by 45.1% to $3.9 million in 2023, then rose by 24.72% to $4.9 million in 2024, then jumped by 124.02% to $10.9 million in 2025, then plunged by 69.97% to $3.3 million in 2026.
• The last three Payables figures came in at $3.3 million (Q2 2026), $10.9 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.